ICPT - Intercept Pharma unlikely to see rival offers other roadblocks analysts say
2023-09-26 16:29:38 ET
More on Intercept Pharma
- Seeking Alpha’s Quant Rating on Intercept Pharma
- Intercept Pharmaceuticals: Alfasigma Pays Premium For M&A Deal That Suits All Parties
- Intercept: Narrowed Market, Concentrated Strategy (Rating Upgrade)
- Drugmakers still chasing potentially lucrative NASH market, despite setbacks
- Intercept Pharma beats Q2 top and bottom line estimates; updates FY23 outlook
For further details see:
Intercept Pharma unlikely to see rival offers, other roadblocks, analysts say